Intrexon | XON - Sales Revenues


Intrexon reported $717K in Sales Revenues for its fiscal quarter ending in June of 2024.





Sales Change Date
Agenus USD 33.7M 500K Mar/2026
Alaunos Therapeutics USD 2K 2K Mar/2025
Amgen USD 10.1B 1.48B Jun/2026
Anika Therapeutics USD 30.62M 2.8M Dec/2025
Arrowhead Research USD 75.23M 1.49M Jun/2026
AstraZeneca USD 15.38B 90M Jun/2026
Bristol-Myers Squibb USD 12.97B 1.48B Jun/2026
Gilead Sciences USD 7.8B 800M Jun/2026
GlaxoSmithKline GBP 8.41B 781M Jun/2026
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Incyte USD 1.67B 400M Jun/2026
Intrexon USD 717K 511K Jun/2024
Karyopharm Therapeutics USD 35.07M 987K Mar/2026
Ligand Pharmaceuticals USD 83.7M 31.98M Jun/2026
MacroGenics USD 20.8M 20.43M Mar/2026
MannKind USD 109.37M 19.17M Jun/2026
Merck USD 16.6B 310M Jun/2026
Novartis USD 14.41B 1.3B Jun/2026
Rigel Pharmaceuticals USD 55.31M 18.47M Sep/2024
Roche Holding CHF 30.36B 14.71B Jun/2026
Sangamo BioSciences USD 356K 125K Jun/2024
Thermo Fisher Scientific USD 11.99B 980M Jun/2026
Veracyte USD 150.32M 11.25M Jun/2026
Xencor USD 51.22M 46.71M Jun/2026